Effect of N-acetylgalactosamine ligand valency on targeting dendrimers to hepatic cancer cells.

Abstract

The display of N-acetylgalactosamine (NAcGal) ligands has shown great potential in improving the targeting of various therapeutic molecules to hepatocellular carcinoma (HCC), a severe disease whose clinical treatment is severely hindered by limitations in delivery of therapeutic cargo. We previously used the display of NAcGal on generation 5 (G5… (More)
DOI: 10.1016/j.ijpharm.2018.04.028

Topics

  • Presentations referencing similar topics